Nkarta, Inc.

• 0Reports naming them
• 2Markets in public records
• 0Regions & countries
• 4Active trials they lead^[1]

^[1] ClinicalTrials.gov, Studies led by Nkarta, Inc. or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.

Public data

Free public data on Nkarta, Inc.

From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.

About our sources

Company facts

Stock listing

NASDAQ: NKTX

Type

Medicines

Source: SEC EDGAR, Company filings, CIK 1787400. Retrieved 13 Nov 2026.

Clinical trials

4 active studies led by Nkarta, Inc., of 4 in all

Source: ClinicalTrials.gov, Studies with Nkarta, Inc. (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.

See them on ClinicalTrials.gov (opens in a new tab)

SEC filings

Annual reports and other filings with the US Securities and Exchange Commission.

Source: SEC EDGAR, Company filings, CIK 1787400.

Open on SEC EDGAR (opens in a new tab)

Trials over time

Studies Nkarta, Inc. leads, by the year they started and their phase

1 2020

1 2021

2022

2023

2 2024

• Phase 1
• Phase 2
• Phase 3
• Phase 4
• No phase (devices, observational)

Source: ClinicalTrials.gov, Studies with Nkarta, Inc. or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.

Markets where public records show them

Markets we cover where free public records show Nkarta, Inc.: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.

• Allogeneic Cell Therapy
• Cancer Immunotherapy

Search all reports for Nkarta, Inc. All companies